Evidence map›Paper›PMID 42244875›Full record

ArticleFrontiers in pharmacology2026

Combining

Dongxin Chen, Hailun Xia, Lu Cao, Haoxin Fu, Yan Chen, Shiqi Jiang, Runjuan Zhan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dongxin Chen *Department of Pharmacy, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China.
Hailun Xia *Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Lu CaoDepartment of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Haoxin FuDepartment of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yan ChenDepartment of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Shiqi JiangDepartment of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Runjuan ZhanDepartment of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Vorolanib is a new-generation multi-targeted kinase inhibitor (MTKI) whose drug-drug interaction (DDI) profile remains largely unexplored. This study combined Methods: Using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), the concentrations of vorolanib and its primary active metabolite X297 were quantified in rat liver microsomes (RLM), human liver microsomes (HLM), recombinant human CYP3A4 (rCYP3A4), and Sprague-Dawley rats. Molecular docking simulations were performed to investigate the binding poses of vorolanib and resveratrol within the active site of CYP3A4. Results: Conclusion: Both

Indexed as

combination therapydrug-drug interactionspharmacokineticresveratrolvorolanib

Identifiers

PMID42244875
PMCPMC13229770

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.